Method of modifying the release profile of sustained release compositions
First Claim
1. A method for the sustained release in vivo of a biologically active agent selected from a biologically active protein, peptide or nucleic acid comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having a biologically active protein, peptide or nucleic acid incorporated therein, and a bisphosphonate compound wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active protein, peptide or nucleic acid from the sustained release composition.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
72 Citations
58 Claims
- 1. A method for the sustained release in vivo of a biologically active agent selected from a biologically active protein, peptide or nucleic acid comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having a biologically active protein, peptide or nucleic acid incorporated therein, and a bisphosphonate compound wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active protein, peptide or nucleic acid from the sustained release composition.
- 3. A method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having a biologically active agent incorporated therein, and a bisphosphonate compound wherein the bisphosphonate compound is separately incorporated into a second biocompatible polymer and is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition.
- 6. A method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having a biologically active agent incorporated therein, and a bisphosphonate compound wherein the bisphosphonate compound is unencapsulated but comingled with the sustained release composition and is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition.
-
14. A pharmaceutical composition comprising:
-
a) a sustained release composition comprising a biocompatible polymer having an effective amount of a biologically active agent selected from a biologically active protein, peptide or nucleic acid incorporated therein; and
b) a bisphosphonate compound, wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active protein, peptide or nucleic acid from the sustained release composition. - View Dependent Claims (15, 24, 25, 26, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
16. A pharmaceutical composition comprising:
-
a) a sustained release composition comprising a biocompatible polymer having an effective amount of a biologically active agent incorporated therein; and
b) a bisphosphonate compound, wherein the bisphosphonate compound is separately incorporated into a second biocompatible polymer and present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. - View Dependent Claims (17, 18, 20, 21, 22, 23, 51, 52)
-
-
19. A pharmaceutical composition comprising:
-
a) a sustained release composition comprising a biocompatible polymer having an effective amount of a biologically active agent incorporated therein; and
b) a bisphosphonate compound, wherein the bisphosphonate compound is unencapsulated but comingled with the sustained release composition and present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. - View Dependent Claims (53, 54, 55, 56, 57, 58)
-
Specification